Business Development News

Trevena Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptors (GPCR) biased ligands, and Forest Laboratories Holding Limited (Forest), a subsidiary of Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased- more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and moksha8, a leader in the commercialization of CNS medicines in Latin America, today announced that they have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd® and potentially other Forest products for the Latin American market.

Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories today announced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran was discovered by Pierre Fabre and jointly developed by Forest Laboratories and Pierre Fabre, under a more...

Forest Laboratories, Inc. (NYSE: FRX) today announced that Forest Laboratories Holdings Limited (Forest), its wholly owned subsidiary, and Janssen Pharmaceutica NV (Janssen) entered into an agreement under which Forest acquired all U.S. patents and other U.S. and Canadian intellectual property for Bystolic^® (nebivolol), which is currently approved in the United States for the treatment of hypertension, thereby eliminating all future royalties. more...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that it has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) (“Clinical Data”) by means of what is known as a short-form merger under Delaware law.

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that its indirect wholly-owned subsidiary, Magnolia Acquisition Corp. (“Magnolia”), has extended the expiration date of its tender offer for all outstanding shares of common stock of, and certain outstanding notes and warrants convertible into the common stock of, Clinical Data, Inc. (NASDAQ: CLDA) (“Clinical Data”) to expire at 12:00 midnight, New York City more...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced the commencement of a tender offer by its indirect wholly-owned subsidiary, Magnolia Acquisition Corp. (“Magnolia”), for all outstanding shares of common stock, $0.01 par value, of Clinical Data, Inc.

AACHEN, Germany & NEW YORK--(BUSINESS WIRE)--The Gruenenthal Group and Forest Laboratories, Inc. (NYSE: FRX), today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.

Forest Laboratories, Inc. (NYSE: FRX), and Cypress Bioscience, Inc. (Nasdaq: CYPB) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which will include a slide presentation, will occur on November 8, 2007 at 10:00am EST. Representing Forest Laboratories will be Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest and representing more...

Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX), today announced that they have entered into a 50/50 partnership in the United States to co-develop and co-market Microbia's first-in-class compound linaclotide. Linaclotide is currently being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C), chronic constipation (CC), and other gastrointestinal disorders.

Forest Laboratories, Inc. (NYSE: FRX) today announced that it has successfully completed the acquisition of Cerexa, Inc., a privately-held biopharmaceutical company based in Alameda, California, in a cash-for-stock transaction with a purchase price of $493.6 million plus a potential $100 million milestone payment.

About Forest Laboratories and Its Products

Forest Laboratories, Inc. (NYSE: FRX) and its wholly-owned subsidiary, Forest Laboratories Holdings Limited, announced today that it and its licensing partner H. Lundbeck A/S have entered into a settlement agreement with defendant Alphapharm Pty Ltd., a subsidiary of Merck KGaA of Germany, regarding its pending patent infringement dispute regarding U.S. Patent Re. No. 34,712, (the '712 patent), which was licensed to Forest by H.